Such confirmation will bear clinical implications as HYP was indeed reported to show efficacy against GBM in a Phase I/II clinical trial when evaluated in recurrent, progressive GBM patients in 6 North American Centers. The gene discussed is PHEX; the disease is glioblastoma.